Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Journal of Indian Academy of Oral Medicine and RadiologyOpen Access

Imiquimod: A Off-Label Drug in the Management of Oral Homogeneous Leukoplakia: A Pilot Study

View Full Paper
Ask AI
Bookmark
Share

Authors

ATA. ThoratMHManjula HebbaleAMAmit Mhapuskar

Discussion

Loading...

Member takes

Overview

Pilot study demonstrates a 50% resolution rate for oral leukoplakia with 5% imiquimod, indicating its potential as an effective noninvasive treatment option.

Key Points

  • Complete resolution of oral leukoplakia was seen in 50% of patients treated with imiquimod.
  • Post-treatment analysis revealed loss of fluorescence in all patients, showcasing its effectiveness.
  • This pilot study involved ten patients diagnosed with oral leukoplakia using 5% topical imiquimod.
  • Findings suggest that imiquimod could be a viable alternative for patients unresponsive to standard therapies.

Cite This Study

Thorat et al. (2025) studied this question.

synapsesocial.com/papers/68dd91c7fe798ba2fc49865ahttps://doi.org/10.4103/jiaomr.jiaomr_133_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Imiquimod for the treatment of oral leukoplakia: A two‐center retrospective study2024 · 4 citations
  2. 2Topical Imiquimod for Oral Cavity Leukoplakia and Dysplasia: A Scoping Review.2026 · 2 citations
  3. 3Imiquimod for Melanoma in Situ and Lentigo Maligna: A Systematic Review2026
  4. 4Modulation of sHLA-G, PD-1, and PD-L1 Expression in Cervical Lesions Following Imiquimod Treatment and Its Association with Treatment Success2024
  5. 5Management of Homogeneous Oral Leukoplakia by Diode Laser and Conventional Blade: A Randomized Controlled Trial2026